Abstract
Tuberculosis (TB) has survived for millennia due to its unique physiochemical properties and its ability to persist in a “dormant” state. Because of these unique properties, the treatment of TB involves multiple drugs for half of a year or longer. Although the incidence of TB has declined in most developing countries, it remains poorly controlled in much of the developing world. This is partly driven by co-infection with HIV in these settings. Concern about this dual epidemic has renewed interest in anti-tuberculosis drugs, and this in turn has led to increasing amounts of pharmacokinetic data regarding TB drugs.
Population pharmacokinetics has proven useful for many disease states, providing a valuable tool with which to explore data and predict future events. It not only generates pharmacokinetic parameter estimates, but it includes patient characteristics (covariates) that may alter those parameters. We review the population pharmacokinetic studies undertaken with anti-TB medications. In addition to the primary medications used in TB treatment (rifampin, isoniazid, pyrazinamide, and ethambutol) we discuss the fluoroquinolones, various software packages, and the covariates that were found to be significant in each study.
Keywords: Population pharmacokinetics, rifampin, rifabutin, rifapentine, pyrazinamide, ethambutol, fluoroquinolones, epithelial lining fluid (ELF), alveolar cell concentrations, monotherapy
Current Pharmaceutical Design
Title: Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment
Volume: 17 Issue: 27
Author(s): Eric Free Egelund, Aline Bergesch Barth and Charles Arthur Peloquin
Affiliation:
Keywords: Population pharmacokinetics, rifampin, rifabutin, rifapentine, pyrazinamide, ethambutol, fluoroquinolones, epithelial lining fluid (ELF), alveolar cell concentrations, monotherapy
Abstract: Tuberculosis (TB) has survived for millennia due to its unique physiochemical properties and its ability to persist in a “dormant” state. Because of these unique properties, the treatment of TB involves multiple drugs for half of a year or longer. Although the incidence of TB has declined in most developing countries, it remains poorly controlled in much of the developing world. This is partly driven by co-infection with HIV in these settings. Concern about this dual epidemic has renewed interest in anti-tuberculosis drugs, and this in turn has led to increasing amounts of pharmacokinetic data regarding TB drugs.
Population pharmacokinetics has proven useful for many disease states, providing a valuable tool with which to explore data and predict future events. It not only generates pharmacokinetic parameter estimates, but it includes patient characteristics (covariates) that may alter those parameters. We review the population pharmacokinetic studies undertaken with anti-TB medications. In addition to the primary medications used in TB treatment (rifampin, isoniazid, pyrazinamide, and ethambutol) we discuss the fluoroquinolones, various software packages, and the covariates that were found to be significant in each study.
Export Options
About this article
Cite this article as:
Free Egelund Eric, Bergesch Barth Aline and Arthur Peloquin Charles, Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470246
DOI https://dx.doi.org/10.2174/138161211797470246 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Glutamine Synthetase and their Potential Application in Medicine
Mini-Reviews in Medicinal Chemistry Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Revision and Implementation of “Clinical Guideline for Tuberculosis and HIV in Prisons”, Great Tehran Prison, Iran
Infectious Disorders - Drug Targets Acetohydroxyacid Synthase: A Target for Antimicrobial Drug Discovery
Current Pharmaceutical Design Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction
Current Vascular Pharmacology Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria
Current Pharmaceutical Biotechnology Chemoinformatics Approach for Building Molecular Networks from Marine Organisms
Combinatorial Chemistry & High Throughput Screening Genome-Scale Metabolic Model as a Virtual Platform to Reveal the Environmental Contribution of Methanogens
Current Biotechnology Design and Development of ChemInfoCloud: An Integrated Cloud Enabled Platform for Virtual Screening
Combinatorial Chemistry & High Throughput Screening Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology Community Expansion and Gene Geography of Sickle Cell Trait and G6PD Deficiency, and Natural Selection against Malaria: Experience from Tribal Land of India
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?
Current Respiratory Medicine Reviews The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Modification and Functionalization of Carboxylated Multiwall Nanotubes with Amantadine, Pregabalin and Alendronate Using Amidation as Anti Cancer Derivatives
Current Nanoscience Transcription Analysis and Small Non-Protein Coding RNAs Associated with Bacterial Ribosomal Protein Operons
Current Medicinal Chemistry Recent Developments in Phytosterol Recovery from Oil Deodorizer Distillates
Current Nutrition & Food Science